ArticleRadiology2023
Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis.
Open access · greenAbstract read
In one paragraph
Article in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Yttrium-90 radioembolization as an in vivo immune modulator: clinical evidence and pharmacologic implications.Frontiers in pharmacology · 2026Article
- Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma.Materials today. Bio · 2025Article
- Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.Bioactive materials · 2025Article
- Interventional oncology and immunotherapy: current status and future perspectives.Frontiers in immunology · 2025Review
- Systemic Immunological Changes After Yttrium-90 Radioembolization: A Pilot Prospective Observational Study-Clinical Insights.Cardiovascular and interventional radiology · 2024Observational
- Role of Interventional Radiology in Managing Primary and Metastatic Breast Cancer.Seminars in interventional radiology · 2024Review
- Immune Effects of Intra-Arterial Liver-Directed Therapies.Journal of vascular and interventional radiology : JVIR · 2024Review
- Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.Journal of interventional medicine · 2023Article
- Immune checkpoint-related gene polymorphisms are associated with acute myeloid leukemia.Cancer medicine · 2023Article
- Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape.International journal of molecular sciences · 2023Review
- Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions.Cancers · 2022Review
- Immune Activation Associated with Transarterial Radioembolization for Breast Cancer Liver Metastases.Radiology. Imaging cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Amy R DeipolyiFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0003-3144-386X
C Bryce JohnsonFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0003-1255-8207
Christopher C RiedlFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).
Henry KuninFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0002-4056-0219
Stephen B SolomonFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0001-5108-1021
Rahmi OkluFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).
Meier HsuFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0002-9519-8560
Chaya S MoskowitzFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0002-2850-8450
Faruk E KombakFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0002-2781-7681
Umesh BhanotFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0001-6656-1239
Joseph P ErinjeriFrom the Department of Surgery, West Virginia University/Charleston Division, Charleston Area Medical Center, 3200 MacCorkle Ave SE, Charleston, WV 25304 (A.R.D.); Department of Radiation Oncology, Inova Schar Cancer Institute, Fairfax, Va (C.B.J.); imagingwest, Hawthorne, NY (C.C.R.); Interventional Radiology Service (H.K., S.B.S., J.P.E.), Department of Epidemiology and Biostatistics (M.H., C.S.M.), and Department of Pathology, Precision Pathology Center (F.E.K., U.B.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Vascular & Interventional Radiology, Laboratory for Patient Inspired Engineering, Mayo Clinic, Scottsdale, Ariz (R.O.).ORCID 0000-0003-1876-727X
Memorial Sloan Kettering Cancer Center · USCharleston Area Medical Center · USWest Virginia University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Background The impact of transarterial radioembolization (TARE) of breast cancer liver metastasis (BCLM) on antitumor immunity is unknown, which hinders the optimal selection of candidates for TARE. Purpose To determine whether response to TARE at PET/CT in participants with BCLM is associated with specific immune markers (cytokines and immune cell populations). Materials and Methods This prospective pilot study enrolled 23 women with BCLM who planned to undergo TARE (June 2018 to February 2020). Peripheral blood and liver tumor biopsies were collected at baseline and 1-2 months after TARE. Monocyte, myeloid-derived suppressor cell (MDSC), interleukin (IL), and tumor-infiltrating lymphocyte (TIL) levels were assessed with use of gene expression studies and flow cytometry, and immune checkpoint and cell surface marker levels with immunohistochemistry. Modified PET Response Criteria in Solid Tumors was used to determine complete response (CR) in treated tissue. After log-transformation, immune marker levels before and after TARE were compared using paired
Indexed as
Breast NeoplasmsCarcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsBiomarkersCutaneous Malignant MelanomaFemaleHumansPilot ProjectsPositron Emission Tomography Computed TomographyRetrospective StudiesBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.